Reimbursement
The 2026 Reimbursement Outlook
How PAMA reset, Z-codes, and MolDx are reshaping molecular economics.
Coming soon
Diagnostic Management & Consulting Group
Building the Future of
Diagnostic Infrastructure.
DMC partners with leading laboratories, healthcare organizations, and innovators to accelerate commercialization, optimize laboratory operations, maximize reimbursement, strengthen regulatory readiness, and expand access to advanced diagnostics.
Est. 2024
Trusted by health systems, reference labs, and life science investors.
Trusted byHealth SystemsReference LaboratoriesMolecular DiagnosticsAnatomic PathologyBiotechnologyMedical DevicePhysician OrganizationsInvestor Portfolios
Impact
Measured outcomes for the organizations shaping the diagnostic economy.
Our engagements are structured around durable financial, operational, and clinical results — not deliverables.
38%
Average lift in first-pass claim acceptance
22 days
Reduction in days-in-A/R across engagements
140+
Laboratory partners across the national network
$1.2B
Revenue under management for client laboratories
Practices
A single firm across the diagnostic value chain.
From CLIA operations and reimbursement to FDA readiness and commercialization — engagements are led by senior operators, not junior consultants.
01
Laboratory Management
End-to-end operational leadership for high-complexity CLIA laboratories.
Explore
02
Revenue Cycle Management
Prior authorization, claims optimization, and denial management engineered for diagnostics.
Explore
03
Commercialization & Market Access
Payer strategy, managed care contracting, and go-to-market for novel assays.
Explore
04
Regulatory & Compliance
FDA and CMS readiness, LDT strategy, inspection preparedness.
Explore
05
Strategic Partnerships
Enterprise and diverse-owned laboratory partnerships across a national network.
Explore
06
Diagnostic Infrastructure
Build-out, integration, and scaling of next-generation diagnostic platforms.
Explore
Laboratory Network
A national network of laboratory partners.
DMC is a woman- and LGBTQIA+-owned firm operating one of the country's most respected consortiums of CLIA laboratories, including a growing platform of minority-, woman-, and LGBTQIA+-owned partners. Together we deliver enterprise scale, geographic reach, and specialized capabilities — from molecular oncology to toxicology and reproductive health.
- · Enterprise partnerships
- · Diverse-owned labs
- · Multi-site integration
- · Specialty diagnostics
Perspectives
What we're seeing across diagnostics, reimbursement, and regulation.
Regulatory
LDTs Under the Final Rule
Building a phased compliance runway for laboratory-developed tests.
Coming soon
Partnerships
The Diverse-Owned Lab Advantage
Unlocking payer, health-system, and enterprise contracts through DMC's partner network.
Coming soon
Why DMC
Operators, not observers.
Our teams have built, scaled, sold, and turned around laboratories. That operator DNA is why hospital executives, boards, and investors engage DMC when the outcome matters.
About the firmBegin the conversation